ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Neuroscience Clinical Development

LATEST NEWSRead more...

15

Jun 2024

XEOMIN® (IncobotulinumtoxinA) Receives Approval for New Therapeutic Use in Switzerland

Merz Therapeutics a division of the Merz Group specializing in neurotoxins has recently obtained approval from Swissmedic the Swiss Agency for Therapeutic Products for XEOMIN

14

Jun 2024

Biosplice and Novo Nordisk Collaborate on Diabetes Solutions

Biosplice Therapeutics Inc a leader in biotechnology specializes in creating innovative treatments through the use of smallmolecule inhibition targeting DYRKCLK kinases Recently Biosplice has formed a strategic alliance with Novo Nordisk to develop new pharmaceutical

14

Jun 2024

NIIMBL and OAGi Partner to Create Open-Source Ontologies for Biopharmaceutical Manufacturing

The National Institute for Innovation in Manufacturing Biopharmaceuticals has transitioned biopharmaceutical manufacturing ontologies to The Open Applications Group facilitating

13

Jun 2024

Helsinn Group and Chugai Pharma Europe Renew Their Collaboration to Distribute AKYNZEO® in the UK and Ireland

Helsinn Group a global pharmaceutical company with over years of experience in supportive care oncology and dermatooncology along with Chugai Pharma Europe Ltd the European subsidiary

13

Jun 2024

12

Jun 2024

Taiho Oncology Europe Announces the Availability of Lytgobi® (Futibatinib) in Germany for the Treatment of Cholangiocarcinoma.

Taiho Oncology Europe GmbH has announced the launch of Lytgobi in Germany following its conditional approval across the European Union Lytgobi is a new oral medication

press releasesRead more...

Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial With CAN10

Cantargia today reported progress in the ongoing phase clinical trial of the CAN antibody Seven dose groups have now been concluded without any safety concerns Furthermore additional receptor occupancy studies confirm that CAN

FDA Approves BLINCYTO® (Blinatumomab) in CD19-positive Philadelphia Chromosome-negative B-cell Precursor Acute Lymphoblastic Leukemia (B-ALL) in the Consolidation Phase

Amgen today announced the US Food and Drug Administration has approved BLINCYTO for the treatment of adult and pediatric patients one month

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

VYNE Therapeutics Inc a clinicalstage biopharmaceutical company developing proprietary innovative and differentiated therapies for the treatment of immunoinflammatory conditions today announced that the first healthy

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

Lisata Therapeutics Inc a clinicalstage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases announced today the successful completion of patient

14 - 17

Jun 2024

18 - 19

Jun 2024

18 - 20

Jun 2024

18 - 19

Jun 2024

5th RNA Editing Summit

Boston, MA, USA

18 - 19

Jun 2024

19 - 21

Jun 2024

CPHI & PMEC China 2024

Shanghai, China

20 - 22

Jun 2024

VACCINESFORUM2024

Porto, Portugal

Thermo Fisher Scientific viral vector services (VVS)
ThermoFisher - Mastering API production at every scale
Future Labs Live - 2024
World Orphan Drug Congress 2024
World Vaccine Congress Europe 2024

TOP ARTICLES

  • 2

    Navigating the Pharma Market: Strategies for Successful Pharmaceutical Sales

    Kate Williamson

    Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

     

  • 3

    Prescription Drugs and Personalized Medicine: A New Era in Pharma

    Kate Williamson

    Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

     

  • 4

    Unveiling Hope: Progress and Challenges in Rare Disease Drug Development

    Kate Williamson

    Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

     

  • 5

    The Impact of Inflation and New Policies on Drug Pricing

    Kate Williamson

    Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

     

KNOWLEDGE BANK

EDITORIAL SECTION